<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04944030</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-2020-19</org_study_id>
    <nct_id>NCT04944030</nct_id>
  </id_info>
  <brief_title>Clinico-biological Data Collection Study of Metastatic Lung Cancer</brief_title>
  <acronym>EPICURE_LUNG</acronym>
  <official_title>Prediction in Silico of Therapeutic Response in a Prospective Cohort Study of Metastatic Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE : Currently, the mechanisms associated with the response or resistance to treatment&#xD;
      are poorly understood and are multifactorial. These mechanisms involve clinical and&#xD;
      biological factors associated with the host and the tumor and possibly the patient's&#xD;
      psycho-social environment.&#xD;
&#xD;
      PURPOSE : This trial will assess the use of a prospective database dedicated to patients with&#xD;
      breast cancers that contains clinical data as well as epidemiological, psychological,&#xD;
      emotional, social, imaging, biological and biopathological data. These data will allow a&#xD;
      creation of new modelling algorithms in order to predict response and resistance to&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective study will be conducted on first line metastatic lung cancer patients. Three&#xD;
      phenotypic groups are identified on immunohistochemistry done at inclusion: on metastatic&#xD;
      sites or lung tumor if local recurrence, usual treatment protocols are often guided by the&#xD;
      following groups:&#xD;
&#xD;
        -  For group 1: SCLC (small cell lung cancer)&#xD;
&#xD;
             -  Carbo or cisplatin + etoposide chemotherapy associated to atezolizumab or&#xD;
                durvalumab&#xD;
&#xD;
        -  For group 2: NSCLC (no small cell lung cancer) without oncogenic addiction:&#xD;
&#xD;
             -  Adenocarcinoma, NOS, sarcomatoïd carcinoma or large cell carcinoma with PDL1&#xD;
                expression level ≥ 50%: Carbo/cisplatin + pemetrexed + pembrolizumab or&#xD;
                pembrolizumab alone.&#xD;
&#xD;
      In case of contra indication of pembrolizumab, treatment will be based on doublet of&#xD;
      chemotherapy with platinum salt +/- bevacizumab - Adenocarcinoma, NOS, sarcomatoïde carcinoma&#xD;
      or large cell carcinoma with PDL1 expression level &lt; 50%: Carbo/cisplatin + pemetrexed +&#xD;
      pembrolizumab.&#xD;
&#xD;
      In case of contra indication of pembrolizumab, treatment will be based on doublet of&#xD;
      chemotherapy with platinum salt +/- bevacizumab&#xD;
&#xD;
      - Squamous cell carcinoma with PDL1 ≥ 50%: Carboplatin + paclitaxel + pembrolizumab or&#xD;
      pembrolizumab alone.&#xD;
&#xD;
      In case of contra indication of pembrolizumab, treatment will be based on doublet of&#xD;
      chemotherapy with platinum salt - Squamous cell carcinoma with PDL1 &lt; 50%: Carboplatin +&#xD;
      paclitaxel + pembrolizumab or pembrolizumab alone.&#xD;
&#xD;
      In case of contra indication of pembrolizumab, treatment will be based on doublet of&#xD;
      chemotherapy with platinum salt&#xD;
&#xD;
      • For group 3: NSCLC NSCLC (no small cell lung cancerwith oncogenic addiction (KRAS&#xD;
      G12c/BRAFV600E/NTRK/ROS1/ALK/EGFR/RET/NTRK/HER2):&#xD;
&#xD;
        -  For which TKI is indicated: TKI as long as possible&#xD;
&#xD;
        -  If TKI is not indicated: doublet of chemotherapy with platinum salt +/- pembrolizumab or&#xD;
           pembrolizumab alone for PDL1 ≥ 50% or doublet of chemotherapy +/- bevacizumab&#xD;
&#xD;
      Further treatment lines are administered according to standard practice. Biological and&#xD;
      histological assessments are performed on specific metastasis biopsy samples done at baseline&#xD;
      and at each progression.&#xD;
&#xD;
      Physical exam, standard laboratory tests, imaging (CT (computerized tomography) scan, PET-CT&#xD;
      (Positron emission tomography-computed tomography) and bone scan (for patients with bone&#xD;
      metastasis) will be performed every 2 to 3 months according to patient group. Clinical,&#xD;
      biological, pathological, epidemiological, socio-economic and multiomic data will be&#xD;
      collected throughout the study duration. These massive data will be used to create new&#xD;
      algorithms in order to help clinicians to predict treatment response&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2030</completion_date>
  <primary_completion_date type="Anticipated">November 2030</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>15 years</time_frame>
    <description>Overall Survival is defined by the delay between the date of inclusion and the date of death or last follow-up assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe response to treatment for each therapeutic sequence</measure>
    <time_frame>15 years</time_frame>
    <description>The response to treatment will be assessed using local radiological review according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate progression free survival (PFS) for each therapeutic sequence</measure>
    <time_frame>15 years</time_frame>
    <description>Progression Free survival is defined by the delay between the first dose of a treatment sequence and the date of documented disease progression or death</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>SCLC (small cell lung cancer)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At each disease progression, patient will have specific interventions :&#xD;
Metastasis biopsy&#xD;
Biomarkers blood, urine and microbiota samples&#xD;
Patient Reported Outcome (PRO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC (no small cell lung lung cancer) without oncogenic addiction:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At each disease progression, patient will have specific interventions :&#xD;
Metastasis biopsy&#xD;
Biomarkers blood, urine and microbiota samples&#xD;
Patient Reported Outcome (PRO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC (no small cell lung lung cancer) with oncogenic addiction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At each disease progression, patient will have specific interventions :&#xD;
Metastasis biopsy&#xD;
Biomarkers blood, urine and microbiota samples&#xD;
Patient Reported Outcome (PRO)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Metastasis biopsy</intervention_name>
    <description>Metastasis biopsy will be performed for multi-omic analysis Biological/Vaccine: Biomarkers blood, urine and microbiota samples Biomarkers blood, urine and microbiota samples for multi-omic analysis Behavioral: Patient Reported Outcome (PRO) Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.</description>
    <arm_group_label>NSCLC (no small cell lung lung cancer) with oncogenic addiction</arm_group_label>
    <arm_group_label>NSCLC (no small cell lung lung cancer) without oncogenic addiction:</arm_group_label>
    <arm_group_label>SCLC (small cell lung cancer)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained from the patient prior to performing any&#xD;
             protocol-related procedures, including screening biopsy, blood sample, faeces and&#xD;
             questionnaires&#xD;
&#xD;
          -  18 years old at time of written consent&#xD;
&#xD;
          -  Patient with histologically confirmed lung cancer&#xD;
&#xD;
          -  Lung cancer metastatic disease or locally advanced not eligible for local curative&#xD;
             treatment intent&#xD;
&#xD;
          -  Patient with metastases that can be biopsied.&#xD;
&#xD;
          -  Performance status ≤ 2 (according to WHO criteria)&#xD;
&#xD;
          -  At least one measurable target on CT scan according to RECIST 1.1&#xD;
&#xD;
          -  Indication of any systemic therapeutic strategy can be performed alongside this&#xD;
             current cohort in accordance with national and / or international recommendations.&#xD;
&#xD;
          -  Patient is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up.&#xD;
&#xD;
          -  Patient must be affiliated to a Social Health Insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other malignancy treated within the last 3 years (except non-melanoma skin cancer or&#xD;
             in situ carcinoma of the cervix)&#xD;
&#xD;
          -  Other neuroendocrine tumour than small cell or large cell carcinoma.&#xD;
&#xD;
          -  Coagulopathy or other pathology that contraindicates biopsy procedures&#xD;
&#xD;
          -  Pregnant or nursing patient&#xD;
&#xD;
          -  Individual deprived of liberty or placed under the authority of a tutor&#xD;
&#xD;
          -  Impossibility to submit to the medical follow-up of this clinical trial for&#xD;
             geographical, social or psychological reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JUDITH RAIMBOURG, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>judith.raimbourg@ico.unicancer.fr</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JUDITH RAIMBOURG, MD,PHD</last_name>
    <phone>0240679900</phone>
    <phone_ext>+33</phone_ext>
    <email>judith.raimbourg@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MARINE TIGREAT</last_name>
    <phone>0240679878</phone>
    <phone_ext>+33</phone_ext>
    <email>marine.tigreat@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancerologie de L'Ouest</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>FREDERIC BIGOT, MD</last_name>
      <email>frederic.bigot@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de L'Ouest</name>
      <address>
        <city>St Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>JUDITH RAIMBOURG, MD, PHD</last_name>
      <email>judith.raimbourg@ico.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 26, 2021</last_update_submitted>
  <last_update_submitted_qc>June 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>Prospective clinico-biological database</keyword>
  <keyword>Multi omic analysis</keyword>
  <keyword>Prediction in silico</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

